Date: Jan 07, 2014 Author: press release Source: Company Data (
click here to go to the source)
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead (BMB) technology with Genetic Analysis of Oslo, Norway.
"Our Barcoded Magnetic Beads and BioCode multiplex analyzers along with Genetic Analysis's GA-map™IBS Dysbiosis Test will enable researchers and healthcare providers access to new ways to address this sometime debilitating disease."
The license from Applied BioCode will give Genetic Analysis access to specific Applied BioCode BMB patents and BioCode analyzers for Molecular Diagnostic testing of microbial imbalances in the GI tract. The license covers both In-Vitro Diagnostic and Life Science Research applications in this area. Genetic Analysis launched their first product, the GA-map™IBS Dysbiosis Test, at the United European Gastroenterology Week (UEGW) Meeting in Berlin, Germany in October 2013.
Genetic Analysis CEO Kari Stenersen explained that "Numerous studies have suggested the role of gut microbiota in Irritable Bowel Syndrome (IBS). However, it is only recently that links between dysbiosis (imbalance in microbiota) and IBS have been explored. Working with leading experts in Scandinavia and Europe, we initiated a series of studies in order to document the use of the GA-map™IBS Dysbiosis Test in various IBS patient populations. We found that Dysbiosis frequency in IBS patients ranged from 35-77% between the clinics. On average, 67% of the IBS patients experienced dysbiosis. The trials have now been extended with feedback from participating investigators backing our decision to bring GA-map™IBS Dysbiosis Test to market." The GA-map™IBS Dysbiosis Test can be run in any accredited molecular diagnostics laboratory.
"We are very pleased to partner with Genetic Analysis in this important and growing area of the market" said Winston Ho, President of Applied BioCode. "Our Barcoded Magnetic Beads and BioCode multiplex analyzers along with Genetic Analysis's GA-map™IBS Dysbiosis Test will enable researchers and healthcare providers access to new ways to address this sometime debilitating disease."
Further terms of the strategic partnership and license agreement were not immediately available.
About Applied BioCode, Inc.
Applied BioCode, Inc. is a privately held Molecular Diagnostics company with headquarters located in Santa Fe Springs,California. Applied BioCode develops, manufactures, and markets highly multiplexed Barcoded Magnetic Beads (128-plex and 4,096-plex) and BioCode analyzers to assist those focused on the molecular diagnostics, bioresearch, and biomarkers validation. Applied BioCode maintains an extensive collaborative network with universities, government laboratories, and industrial partners. Several of Applied BioCode's partners have adapted their molecular diagnostic assays to the Barcoded Magnetic Bead format. This approach enables them to optimize efficiency and resources and leverage those to help its customers maximize the benefit of its powerful tools and collaborative networks.
About Genetic Analysis AS
Genetic Analysis AS is a private Norwegian molecular diagnostics company focused on microbial imbalances of the GI tract. They are positioned to become a world leader molecular diagnostics of gut bacterial imbalances in various diseases. By utilizing the DNA-based GA-map™array technology, profiles of a patient's gut microbiota is quickly generated and can be related to various health conditions.
For more information, please contact:
Applied BioCode, Inc.
Winston Z. Ho, President